Good morning, everyone, and thank you for joining us for Mativ's third quarter 2024 earnings call. Before we begin, I'd like to remind you that comments included in today's conference call include forward-looking statements. Actual results may differ materially from these comments for reasons shown in detail in our Securities and Exchange Commission filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Some financial measures discussed during this call are non-GAAP financial measures. Reconciliations of these measures to the closest GAAP measures are included in the appendix of the earnings release. Unless stated otherwise, financial and operational metric comparisons are to the prior year period and relate to continuing operations. The earnings release issued yesterday afternoon is available on our website at ir.mativ.com. With that, I'll turn the call over to Julie.

Thanks, Chris. Good morning, everyone, and thank you for joining our call. We appreciate the opportunity to share our third quarter results with you, outline a number of initiatives we've undertaken to drive continued improved performance, and provide an outlook on the remaining quarter of 2024. Sales were up 1% organically and essentially flat year-over-year on a reported basis. Volume improvements in most of our product categories were partially offset by lower demand in film, which was impacted by ongoing challenges in the automotive and construction end markets, as well as lower productivity in one of our largest film plants. I'll provide more color on this in a moment. For the total Mativ, from a bottom-line perspective, I'm pleased to report that Q3 results showed meaningful adjusted EBITDA improvement, up 10% year-over-year and adjusted EBITDA margin up 110 basis points year-over-year. Primary drivers were increased volume in filtration and our overall SAS segment, as well as lower manufacturing costs. Let me touch on SAS first, which delivered adjusted EBITDA up almost 20% and increased margin of 200 basis points. Within SAS, health care was very strong, followed by label, commercial print, and release liners. We see continued solid volume and growth as we enter Q4, particularly in release liners in North America as we ramp up and qualify our newest asset in Mexico. Overall, FAM performance in the quarter was mixed with solid results in filtration and challenging results in advanced film. Let me provide a bit more color on this part of our business and what we are doing to improve film performance going forward. First, in our filtration category, revenues were up almost 6% led by growth in air filtration used in HVAC and air pollution control. Our largest end market in filtration is transportation, which was up over 5%, and continues to have a very healthy pipeline of new products and opportunities in 2025. As a reminder, in transportation filtration, we are mainly driven by the aftermarket and about 50% of our media goes into heavy-duty fleet vehicles. These markets remain much healthier than the overall automotive market. Now turning to advanced film, which is part of our FAM segment. As a reminder, the largest part of this category is paint protection film that is applied to new cars, typically at the time of purchase or immediately following. Another large part is optical film, which is often used on the exterior and interior of office buildings. These categories are heavily influenced by the automotive and construction markets, both of which remain soft, and which impact about 85% of our film sales. Additionally, paint protection film, which makes up about 1/4 of our films revenue, and with historically high margins, is a category where we are seeing increased competition from Asia with lower performance, less costly products. And lastly, we underperformed at our largest films plant, impacting margins in Q3 and Q4 as we sell through high-cost inventory. Given the rapidly evolving markets and the diversity of new applications that we have in development, we've assembled a tiger team to develop quick and aggressive actions to improve results over the next 12 months. This effort is focused on demand generation and operational performance centered around three platforms. First, accelerating our presence in targeted markets, particularly in medical and optical films, such as advanced wound care, smart glass, and interlayer applications. These applications play to our strength in advanced materials and technology development. One example of extending our market reach is the partnership we recently announced with Miru company to develop innovative smart glass products for autos and buildings. These products feature increased energy efficiency, temperature control, and improved aesthetics. We recently showcased this partnership and samples at the International Glasstec trade show and received very positive feedback from key industry leaders who expressed strong interest in this new state-of-the-art technology and the ability to provide improved performance and reduced carbon footprint versus today's solutions. Turning to medical films, we have invested in a new medical films line in the U.K. that will start up in Q1 of 2025 and provides improved quality and capacity for growth in our healthcare applications, giving us over $15 million of incremental revenue opportunities over the next four years. The second platform is providing a unique capability and holistic supply chain solution, a One Mativ solution, for customers to procure not only the base film product but the fully coated and converted film product for their application. Today, most customers are sourcing this solution through three or more suppliers. Unique to Mativ, we can provide all four steps, improving quality and reducing our customers' supply chain complexity, cost, and lead times. The third platform is aggressive cost reduction in our manufacturing sites as well as how we develop new products. For instance, we're focused on accelerating qualifications of more cost-efficient resins and raw materials and introducing a mid-tier product to combat increased imports from Asia. Lastly, we have a core part of the tiger team in our largest film site focused on driving sustainable, improved productivity, quality, and operational performance. The advanced film turnaround effort is similar to the approach we took over the course of 2023 to improve performance in healthcare. The year-to-date results of this effort in health care are above-market organic sales growth of more than 5% versus the prior year and significantly improved profitability that has exceeded our expectations. Based on this similar effort and the outcome, I'm confident we will successfully improve results in advanced films over the course of the next 12 months. I'll now turn to some of our high-growth categories where we are investing for additional capacity. We've previously talked about the investments we are making in filtration, specialty tapes, and release liners, and I just touched on the new investment in the U.K. to expand our medical film capacity. We also recently announced an investment in specialty tape to support our Polyflex and athletic tapes category with a new line in our facility in Canada. We are close to capacity in this category and have significant upside opportunities and commitments from key customers for future growth. We expect the line to start up in early 2026 and support over $20 million in incremental revenue once fully utilized by the end of year three, with almost 50% of the volume expected to be realized in year one. Combined, the investments in growth that we've announced throughout 2023 and 2024 are expected to provide incremental revenues of over $115 million in the next three to four years. Additionally, our commercial teams are executing well to drive sustained sales growth. Here are just a few examples. In FAM, we've realized over $10 million in share gains with a number of HVAC and air pollution control customers. We also negotiated over $10 million in new customer agreements that will begin mid-2025 and continue to add to our large pipeline for product development with key customers. In SAS, our momentum is strong. We talked about a new leader, Ryan Elwart, that we hired to run this segment earlier this year, and he and his SAS team are doing exactly what we wanted from them, which is driving our commercial excellence efforts and focusing on new demand generation opportunities. As evidence of this, we recently signed a new long-term commitment for release liners with one of the largest consumer goods companies in North America. In paper and packaging, we previously told you about a major win in our digital print category worth over $10 million annually, and I'm happy to share that we have secured additional commitments totaling another $5 million in opportunities, starting in midyear 2025. In health care, we are launching a new sterilizable medical paper product. This is a reinforced and partially bio-based solution for the health care packaging sector and will launch in the first half of next year. I'm very pleased with the sales pipeline that we have in place and with the team driving it. Finally, as a manufacturing company, we are always focused on reducing our costs and optimizing our assets. During this most recent quarter, we added to this list, divesting a small, nonstrategic and high-cost facility in Massachusetts. This past week, we closed on the sale of our plant in the Netherlands, which is expected to have an immediate accretive effect on our operating margin and will further reduce the complexity of our portfolio by exiting a category. With that, since the merger, we have streamlined our footprint from 48 sites to now 35 sites and reduced our outside warehouses by over 25%. Taken together, these actions have and will continue to reduce our costs, improve the customer experience, and improve our margins, especially as demand returns to more normalized levels. We will continue to evaluate our portfolio and our manufacturing and warehousing footprint for further opportunities to reduce complexity and unlock incremental value. With that, I'll turn it over to Greg for a more detailed discussion of our financial performance.

Thanks, Julie, and good morning, everyone. Consolidated net sales from continuing operations for the quarter were $498.5 million compared to $498.2 million in the prior year. Sales were up 1.4% year-over-year on an organic basis and selling prices were essentially flat versus the prior year, while currency was favorable. Adjusted EBITDA from continuing operations was $60.8 million, up 10% from $55.4 million in the prior year. Improved distribution and manufacturing costs and lower SG&A expenses represented a combined $7 million favorable impact, which was partially offset by $2 million of lower contribution from mix. Adjusted EBITDA margin increased 110 basis points year-over-year. Turning to each of our segments. Net sales in our Filtration & Advanced Materials segment of $190 million were down 3% versus Q3 of 2023. As Julie mentioned, we reported higher volumes in our filtration categories that were more than offset by lower volumes in our advanced films category, as well as lower selling prices in the segment. FAM adjusted EBITDA of $36 million was down almost 7% year-over-year, reflecting the effects of lower volumes in our high-margin advanced films category and lower selling prices in the segment. We partially offset these pressures with higher volumes in our filtration categories, lower SG&A expenses, and improved manufacturing efficiencies. In our Sustainable & Adhesive Solutions segment, net sales of $309 million were up more than 4% from last year on an organic basis and up more than 2% on an as-reported basis. Organic growth reflects the higher volumes across all of our end markets and higher selling prices. SAS generated strong adjusted EBITDA performance of $41 million, which was up almost 20% year-over-year. Adjusted EBITDA margin increased 200 basis points versus the prior year. The year-over-year performance reflected favorable manufacturing and distribution costs, favorable relative net selling price versus input cost, and higher volumes, partially offset by unfavorable mix and slightly higher SG&A expenses. Turning to a few of the corporate items. Unallocated corporate adjusted EBITDA expense of around $17 million was down more than 7% versus the prior year. As a reminder, we still expect unallocated to be around $80 million for the full year. Interest expense of $18 million increased 9% from the prior year primarily due to higher interest rates on our floating rate debt in 2024, coupled with a higher revolver balance in the current period. When taking hedges into account, approximately 75% of our debt is at a fixed rate and matures on a staggered basis between 2027 and 2029. In late September, we went to market with a $400 million bond offering that priced at 8% and settled subsequent to the end of the quarter on October 7. We were able to take advantage of the then prevailing market rates and risk premiums that allowed us to reach a favorable outcome for Mativ, essentially providing certainty in what has become a more volatile interest rate environment. We used the proceeds from the bond offering to pay off our outstanding $350 million bond that was due in 2026, as well as the $43 million portion of our Term Loan B. With these changes, we expect our go-forward annual interest expense to be $75 million per year. Other expense of $12.7 million increased $12.4 million compared with the prior year period, largely due to other asset-related charges in connection with the two facility rationalizations Julie outlined earlier, as well as losses on foreign exchange. Our tax rate was 13% in the quarter. This low tax rate was driven by one-time tax adjustments which, if excluded, would yield an effective tax rate of 21%. For modeling purposes, however, we suggest using a normalized tax rate of 24%. At the end of the quarter, net debt was $981 million and available liquidity was $463 million. Our net leverage ratio, as defined in our credit agreement, was 4.1x, sequentially flat with Q2. Our number one priority for cash flow utilization is and continues to be deleveraging and debt reduction, and our target leverage range is 2.5x to 3.5x. We did not repurchase any shares during the quarter. Our intent continues to be to opportunistically repurchase shares to offset dilution, and the priority of cash flow remains on paying down debt. Turning to our outlook for Q4 2024. We do not see evidence of a change in demand from what we have seen in Q3. We recognize a number of our categories are also subject to normal year-end seasonality. Therefore, we expect Q4 sales to be up mid-single digits versus last year, and Q4 adjusted EBITDA to be down low double digits versus last year. This is driven by timing of incentives, product mix, timing of maintenance outages, and extended downtime over the holiday season versus Q4 2023. We will provide more detail on our expectations for the next fiscal year during our earnings call in February. For modeling purposes, we are now planning for 2024 full-year capital expenditures of approximately $50 million, down from the previously communicated $60 million, and we expect our depreciation and amortization expense to be around $100 million.

Thank you, Greg. What you should take away from this call is that while the pace of demand is slower than expected, we are focused and taking actions to offset the impact, grow share, and capture incremental value when markets improve. This includes new programs, resources, and products that result in new business with examples provided earlier today and investments in partnerships in key categories of filtration, release liners, specialty tapes, and medical and optical films, where we have upside growth opportunities. We continue to simplify and streamline our operations, including divesting noncore business lines and consolidating assets, warehouses, and manufacturing plants. We've outlined our turnaround plan for an underperforming category, advanced films, which mirrors our demonstrated success within health care. Lastly, we are aggressively driving out costs with over $20 million of nonoperating cost reductions this year. All of these actions are the right things to do, and I appreciate the support from our Board in making these decisions and from our teams in making them happen. One last item to highlight: we will be publishing our 2023 ESG report over the course of this month. We look forward to sharing with you our continued commitment to being responsible stewards of the environment, maintaining a diverse and caring culture, and having strong corporate governance practices. Thank you for joining us this morning, and please open the line for questions.

Thank you, Ms. Schertell. We have our first question from Daniel Harriman with Sidoti & Company. Your line is open. Please go ahead.

Hey, good morning, guys. Thanks for taking my questions. I'll start off with two quick ones, and then I'll get back in the queue afterwards. But Julie, I know you provided a lot of information to us on the tiger team initiative. I'm just wondering if you could provide a little bit more information about when that process started and maybe what demand generation ideas you're most excited about within that. And then on the Q4 guide, the increase in revenue and the decrease in EBITDA year-over-year, that disconnect, is that made up mostly just of expectations for poor performance in films? Or is there something else to look for there?

Thanks, Dan. Let me start with your first question on films. From a tiger team standpoint, it really started this quarter. So films are down about 10% this year versus last year, and it's a category that has historically had very high margins. So, it has a disproportionate impact on our bottom line. The tiger team is focused around three primary issues: how we battle the headwinds of weak markets in automotive and construction; the second is increased competition from Asia with lower performance alternatives; and the third is poor operational performance in one of our largest plants in North America. As I work my way backwards, the most straightforward issue for us to address is the low performance in our own plant. That's all within the four walls of Mativ. We know what good looks like. We know how to operate well. We have a very strong facility that makes these products in China, allowing us to better share best practices to drive improvements in productivity, speed, quality, and overall performance in the supply chain to our customers. The second opportunity there, and one that I am most excited about, is this One Mativ potential solution. It is a place where I've mentioned a couple of times, our customers are buying from three to four different suppliers, and we are in a unique position to provide all of those services and capabilities to our customers – the base film, the topcoat, the PSA, and the converted product. We've got customers who are very interested and engaged with us on that process. It will take some time because there's a fair amount of qualification that has to happen, but it's a big opportunity that can really change the supply chain capabilities for us and our customers in this space. The last issue is how we combat weak markets continuing in automotive and construction. As a reminder, about 85% of our films are impacted by the automotive and construction markets. To address this, we are aggressively expanding our addressable markets in a couple of ways: one is with an investment into medical films capabilities in the U.K. that will start up in 2025, and the other is in our optical films business. We recently announced a partnership with a company called Miru. The technology we are working on provides glass capabilities that increase energy efficiency, reduces carbon footprint, and improves aesthetics. We have a large EV manufacturer as our first customer and expect to launch that product in early 2026. So again, it's going to take time – these are highly technical and require a lot of qualification – but they represent big value opportunities. Paint protection film remains crucial for us. In the interim, we have the opportunity while the markets are weak to provide more resilience in this category by extending our end-use applications. I'm confident in the turnaround efforts we have in place. It's a very similar approach to what we used in health care, as I mentioned on the call, and the results in health care are exceeding our expectations. I look forward to the team's continued performance; they've already had key milestone report outs to me and are making great progress.

And then, Daniel, this is Greg. I'll take your second question regarding the expectations for the fourth quarter and the increased year-over-year sales, but decreased year-over-year EBITDA. You are correct; we are expecting strong sales primarily driven in the SAS segment for Q4. However, the films business is weighing down on the EBITDA. That's one of the largest factors. Additionally, there is some price input timing, and there are some pockets of pricing within FAM that we're working on to maintain and gain volume. On the cost side, the overhead reduction program that we talked about earlier is flowing through to the P&L. From a comp standpoint, we did have a much lower incentive accrual last year that we're comping against. Finally, to a lesser extent, the timing of the holidays and the outages I mentioned is the last impacting item.

Hi, good morning and thank you for taking my questions. I appreciate the detail on Q4 and all the inputs going into it. But I was wondering if you could talk about what your customers are telling you as you enter '25, the Q4 shutdowns and everything. Are they ready to pick back up again? Is it too early to tell? How should we think about the velocity exiting the holidays?

Yes. Thanks for the question, Jon. I would say that demand recovery remains sluggish, and I think we're seeing that all around us. The PMI fell again this month, hitting the lowest point since COVID. This indicates that the manufacturing and materials industries are not yet healthy, and they are still contracting, which we are directly correlated to. We're not seeing indicators of a changing demand profile in the near term. It almost seems like we got a false positive in the spring that quickly returned to a sluggish environment. Until we see interest rates decrease more in auto, home, DIY, and remodeling, we expect to experience this lower level of demand. From our customers' standpoint, they are in the same position. They're not seeing meaningful indicators and remain conservative in their willingness to build inventory, given past supply chain challenges over the last couple of years. There are pockets of strength, primarily in filtration, particularly in air filtration and transportation filtration, but this is mostly driven by the aftermarket. I'm really excited about the pipeline we have in our SAS segment, with aggressive growth opportunities in release liners particularly in North America, and new commitments and agreements from leading customers in that geography set to launch next year. We also have new commitments in our health care business and significant opportunities in our tape business. They may not all materialize, but we just need a couple to hit to have a significant impact, which will come mid to late 2025. So while I'm excited about the pipeline and our teams' efforts, I cannot suggest there's a healthy demand environment emerging at this time.

Okay, fair enough. And any thoughts on the potential for a more aggressive tariff environment or perhaps a more or less tax environment and how that might affect your business if you're planning for anything like that in your strategic level planning?

Yes. If you're talking about potential new administration, I think it's a little too early to speculate on what that could do for us. From a tariff standpoint, we have low exposure on the cost side, as about 88% of our spend is sourced from a site in the home region. That's a very advantageous position. If we expect incremental tariffs on Chinese-made goods sold into the U.S., that could be likely, which might benefit us particularly in the films business. We're currently seeing an acceleration of lower-cost and lower-performance film products coming into North America and Europe from Asia. So, there might be an advantage for us there.

Sure. I'll take that, Jon. Our target still remains the same, the 2.5x to 3.5x range. Based on the prolonged market recovery, we expect to still hit that, but it will likely be more in the 2026 timeframe, making progress toward that over 2025.

Just two more quick ones for me, if that's okay. First, can you expand a little bit upon the two most recent facility closures? Maybe just a little bit more detail on the rationale there and the potential for more closures moving forward as you optimize the footprint? And then with the reduction in CapEx spend, what are your expectations for the impact on cash flow for the year?

Sure. Thanks, Dan. The divestitures we announced this quarter included a site in the Netherlands, which produced paper for dye sublimation products. With its sale, we have exited that business. It was a nonstrategic, breakeven type of EBITDA business for us and will be better in the hands of the buyer, who has plans to invest in the business. We also exited a site in Massachusetts that supported our paper business, too. Both sales support our strategy to reduce complexity, prune nonstrategic and non-accretive sites and categories, and accelerate growth by focusing our efforts in areas where we have unique capabilities to win in the marketplace. The impact of those, combined, is about a $50 million reduction in revenue that we will see next year and about a $1 million increase in EBITDA next year.

Yes. I'll take your second question, Dan, regarding the CapEx and cash flow. Based on the suppressed markets we have been seeing, we continue to revisit the capital plan for the year, which is a big reason why we reduced it from $60 million to $50 million this year, primarily due to a reduction in discretionary sustaining and maintenance capital, alongside some deferral of IT capital expenditure. As for cash flow, Q3 was a strong quarter for cash flow, and we expect Q4 cash flow to remain positive, albeit lower than Q3, primarily due to the lower CapEx spend.

Thank you for joining us this morning on our Q3 2024 earnings call. We look forward to connecting with you throughout the quarter and on our next earnings call in February. Have a wonderful day.

Thank you. This concludes today's call. Thank you all for joining. You may now disconnect your lines.